Kang Yun Lu

Ms. Kang Yun Lu


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Cell Transplantation
Verified
Journal Article
Open access
PDF file
KLKang Yun Lu
Kang Yun Lu
KDKingsley Theras Primus Dass
Kingsley Theras Primus Dass
STSheng-Feng Tsai
Sheng-Feng Tsai
HCHong-Meng Chuang
Hong-Meng Chuang
SLShinn-Zong Lin
Shinn-Zong Lin
HHHorng-Jyh Harn
Horng-Jyh Harn
Mammalian fat comprises white and brown adipose tissue (WAT and BAT, respectively). WAT stores energy, whereas BAT is used for thermogenesis. In recent years, the incidence of obesity and its associated disorders have increased tremendously. Considering the thermogenic capacity and decreased levels of BAT with increasing age, BAT can be used as a suitable therapeutic target for the treatment of obesity and diabetes. In several studies, using positron emission tomography and computed tomography images, adult humans have been shown to have functional BAT in interscapular fat. Results of these basic research studies on BAT have shed light on the new components of transcriptional regulation and the role of hormones in stimulating BAT growth and differentiation. In this review article, we have summarized the thermogenic regulators identified in the past decades by focusing on peroxisome proliferator-activated receptor gamma/uncoupling protein 1 activators, branched-chain amino acids, fatty acids (lipokine), and adenosine monophosphate-activated protein kinase mediators. We have also presented the progress of a few ongoing clinical trials aimed at the treatment of obesity and its associated metabolic disorders. The main purpose of this review was to provide a comprehensive introduction to the latest knowledge of the representative thermogenic regulators for the treatment of obesity. The fat combustion capacity of BAT may have great potential and can be considered as a suitable target for the therapeutic application of drugs from bench-to-bed treatment of obesity and the associated diseases.

28 January 2018 in Molecules
Verified
Journal Article
Open access
PDF file
HTHsiao-Chien Ting
Hsiao-Chien Ting
CCChia-Yu Chang
Chia-Yu Chang
KLKang Yun Lu
Kang Yun Lu
HCHong-Meng Chuang
Hong-Meng Chuang
STSheng Feng Tsai
Sheng Feng Tsai
HHHorng-Jyh Harn
Horng-Jyh Harn
Traditional Chinese medicine has been practiced for centuries in East Asia. Herbs are used to maintain health and cure disease. Certain Chinese herbs are known to protect and improve the brain, memory, and nervous system. To apply ancient knowledge to modern science, some major natural therapeutic compounds in herbs were extracted and evaluated in recent decades. Emerging studies have shown that herbal compounds have neuroprotective effects or can ameliorate neurodegenerative diseases. To understand the mechanisms of herbal compounds that protect against neurodegenerative diseases, we summarize studies that discovered neuroprotection by herbal compounds and compound-related mechanisms in neurodegenerative disease models. Those compounds discussed herein show neuroprotection through different mechanisms, such as cytokine regulation, autophagy, endoplasmic reticulum (ER) stress, glucose metabolism, and synaptic function. The interleukin (IL)-1β and tumor necrosis factor (TNF)-α signaling pathways are inhibited by some compounds, thus attenuating the inflammatory response and protecting neurons from cell death. As to autophagy regulation, herbal compounds show opposite regulatory effects in different neurodegenerative models. Herbal compounds that inhibit ER stress prevent neuronal death in neurodegenerative diseases. Moreover, there are compounds that protect against neuronal death by affecting glucose metabolism and synaptic function. Since the progression of neurodegenerative diseases is complicated, and compound-related mechanisms for neuroprotection differ, therapeutic strategies may need to involve multiple compounds and consider the type and stage of neurodegenerative diseases.

1 January 2021 in Cell Transplantation
Verified
Journal Article
Open access
PDF file
STSheng Feng Tsai
Sheng Feng Tsai
KLKang Yun Lu
Kang Yun Lu
HCHong-Meng Chuang
Hong-Meng Chuang
CLChing-Ann Liu
Ching-Ann Liu
Until July 29th, the number of confirmed coronavirus (COVID-19) cases worldwide has risen to over 16 million, within which 655 k deaths. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) emerges as the 11th global pandemic disease, showing the highest infectivity and lowest infection fatality rate. In this review, we compare the immunopathology among SARS-CoV, Middle East respiratory syndrome coronavirus, and SARS-CoV2. SARS-CoV2 is similar to SARS-CoV; it can cause lymphocytopenia and a rising granulocyte count. Here we point out the human body and concentrated society make for an excellent incubator for virus evolution. Most research energies put into developing the SARS-CoV2 vaccine are trying to block virus infection. Sixty-five percent of severe patients die with multiple organ failure, inflammation, and cytokine storm, which indicates that the patient’s immune system maintains functionality. Finding a way to trigger the specific T cell subset and plasmablast in our body is the best shot to get away with SARS-CoV2.

11 July 2025 in Medicine
Verified
Journal Article
Open access
XHXiaoyan Huang
Xiaoyan Huang
MWMiaohui Mm Wu
Miaohui Mm Wu
ZWZexiang Wu
Zexiang Wu
KLKang Yun Lu
Kang Yun Lu
YLYancheng Lin
Yancheng Lin
YZYi Zhang
Yi Zhang
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent metabolic disorder characterized by liver fat accumulation. Family with sequence similarity 19 member A5 (FAM19A5), a cytokine involved in metabolic regulation, may serve as a potential biomarker for MASLD diagnosis and treatment. A cross-sectional study was conducted on 37 participants from Quanzhou First Hospital between January and April 2024, including 18 MASLD patients and 19 healthy controls. Demographic data, anthropometric measurements, and clinical parameters were collected, and plasma FAM19A5 levels were quantified using Enzyme-Linked Immunosorbent Assay. After univariable analysis to screen variables associated with FAM19A5 levels, significant variables were included and potential confounders were adjusted for, followed by constructing multivariable linear regression models via stepwise variable selection. All statistical analyses were carried out using SPSS 26.0. Significant negative correlations were found between FAM19A5 levels and MASLD, body mass index, and total cholesterol. The expression of FAM19A5 was notably lower in MASLD patients, suggesting its potential role in the disease’s pathophysiology. FAM19A5 could be a novel diagnostic biomarker for MASLD, with lower expression levels associated with the disease. Further research involving a broader patient population is needed to establish causality and explore its clinical implications.